GALM
Galactose mutarotase
Also known as: GALM_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96C23
- Gene
- GALM
- Ensembl
- ENSG00000143891
- Chromosome
- 2
- Canonical length
- 342 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
This gene encodes an enzyme that catalyzes the epimerization of hexose sugars such as glucose and galactose. The encoded protein is expressed in the cytoplasm and has a preference for galactose. The encoded protein may be required for normal galactose metabolism by maintaining the equilibrium of alpha and beta anomers of galactose.[provided by RefSeq, Mar 2009]
Canonical amino-acid sequenceUniProt
342 residues, UniProt reviewed canonical sequence.
>Q96C23|GALM
1 MASVTRAVFG ELPSGGGTVE KFQLQSDLLR VDIISWGCTI TALEVKDRQG RASDVVLGFA
61 ELEGYLQKQP YFGAVIGRVA NRIAKGTFKV DGKEYHLAIN KEPNSLHGGV RGFDKVLWTP
121 RVLSNGVQFS RISPDGEEGY PGELKVWVTY TLDGGELIVN YRAQASQATP VNLTNHSYFN
181 LAGQASPNIN DHEVTIEADT YLPVDETLIP TGEVAPVQGT AFDLRKPVEL GKHLQDFHLN
241 GFDHNFCLKG SKEKHFCARV HHAASGRVLE VYTTQPGVQF YTGNFLDGTL KGKNGAVYPK
301 HSGFCLETQN WPDAVNQPRF PPVLLRPGEE YDHTTWFKFS VALocalizationUniProt · AlphaFold · HPA
Whether an antibody against GALM can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.21
- Highest tissue expression
- 112 nTPM
Expression across tissuesHPA
Tissue
- kidney: 112 nTPM
- adrenal gland: 90 nTPM
- liver: 68 nTPM
- duodenum: 67 nTPM
- small intestine: 50 nTPM
- fallopian tube: 34 nTPM
Single-cell type
- t-cells: 215 nCPM
- adrenal cortex cells: 210 nCPM
- enterocytes: 178 nCPM
- proximal tubule cells: 161 nCPM
- peritubular myoid cells: 147 nCPM
- müller glia: 144 nCPM
Immune cell
- T-reg: 69 nTPM
- basophil: 39 nTPM
- memory CD4 T-cell: 33 nTPM
- MAIT T-cell: 32 nTPM
- memory CD8 T-cell: 31 nTPM
- gdT-cell: 22 nTPM
Brain region
- choroid plexus: 13 nTPM
- thalamus: 11 nTPM
- midbrain: 8.7 nTPM
- white matter: 8.3 nTPM
- cerebellum: 8.2 nTPM
- spinal cord: 7.8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GALM.
Disease | AllUniProt
Conditions GALM is implicated in, by any mechanism.
- Galactosemia 4 (GALAC4) MIM:618881
Disease | GeneticClinVar
6 pathogenic / likely-pathogenic of 124 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Galactosemia 4
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.5
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.15
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- carbohydrate metabolic process
- galactose catabolic process via UDP-galactose, Leloir pathway
- galactose metabolic process
- glucose metabolic process
Molecular functions
- carbohydrate binding
- aldose 1-epimerase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Galactose mutarotase-like domain superfamily
- Aldose 1-/Glucose-6-phosphate 1-epimerase
- Glycoside hydrolase-type carbohydrate-binding
- Aldose 1-epimerase/Galactose mutarotase
- Aldose 1-epimerase, conserved site
- Galactose mutarotase-like
- Aldose 1-epimerase
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GALM as an antibody target. Whether an autoantibody or antibody against GALM could matter depends on whether native GALM is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GALM is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label GALM as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...